Shanghai Laishi: human thrombin has been approved for drug supplement application
Financial Associated Press, December 15 (Xinhua) - Shanghai Laishi announced that the company's human thrombin obtained the notice of approval of drug supplementary application.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Yesterday 02:13 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Nov 08, 2022 08:32 AM
Briefing Apr 02, 2022 05:34 PM
· Technology
China network security industry innovation and development alliance was officially established
Briefing Feb 17, 2022 07:29 PM
· Technology
Chinese mission to the European Union: express strong dissatisfaction and firm opposition to the European Parliament's arbitrary discussion of China's internal affairs
Briefing Feb 17, 2022 08:29 AM
· Technology
CITIC Securities: metauniverse is a future trend that cannot be underestimated, but it is still in the early stage of concept and marketing
See more
Read next
Insight
In-depth
Insight
In-depth